3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients 12 years and older with chronic graft versus host disease after failure of at least two prior lines of systemic therapy.

Full reimbursement criteria are available on the British Columbia Pharmacare website and Ontario Drug Benefit website.

Read Sanofi press release